file of therapeutic nicotine products when used as directed(4). Therapeutic nicotine is recommended as a first-line treatment for smoking addiction in United States, United Kingdom and World Health Organization (WHO) guidelines(2,3,5). To date, GSK's therapeutic nicotine has helped more than six million people around the world quit smoking, and as a result, has greatly reduced their exposure to the risks of cancer and other smoking-related diseases(6).
These products are designed specifically to break the addiction cycle by offering a gradual, controlled delivery of nicotine to the body, helping to relieve withdrawal symptoms.
About GlaxoSmithKline Consumer Healthcare
GlaxoSmithKline Consumer Healthcare is one of the world's largest over-the-counter consumer healthcare products companies. Its more than 30 well-known brands include the leading smoking cessation products, NicoDerm(R) CQ and Commit(R), NiQuitin and Nicabate, as well as many medicine cabinet staples such as Aquafresh(R), Panadol(R), Crocin(R), Horlicks(R) and Sensodyne(R). GlaxoSmithKline Consumer Healthcare continues to develop innovative products to help all smokers find their best support system and achieve their goal of being cigarette free.
GlaxoSmithKline is one of the world's leading research-based pharmaceutical and consumer healthcare companies. GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
(1) Jha, et al; A Nationally Representative Case - Control Study of Smoking and Death in India; NEJM, 2008
(2) World Health Organization. WHO Report on the Global Tobacco Epidemic, 2008. Geneva: World Health Organization; 2008 [cited 2008 Mar 21]. Available from: http://www.who.int/tobacco/mpower/en/
(3) Fiore MC, Jaen CR, Baker TB, e
Page: 1 2 3 4 Related medicine news :1
|SOURCE GlaxoSmithKline Consumer Healthcare|
Copyright©2009 PR Newswire.
All rights reserved
. GlaxoSmithKline Consumer Healthcare Helps to Bridge Oral Care Gap in Appalachia2
. Activplant Corporation Announces Global Agreement with GlaxoSmithKline3
. GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer4
. GlaxoSmithKlines Drug Will Become New Clinical Gold Standard by 2012 for the Treatment of Relapsed/Refractory CLL5
. GlaxoSmithKline Awards Ten Area Healthcare Nonprofits with $40,000 Each in Funding6
. GlaxoSmithKline and Dynavax Announce Worldwide Strategic Alliance : – Developing First-in-Class Endosomal TLR Inhibitors for Autoimmune and Inflammatory Diseases – 7
. GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists8
. GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program9
. GlaxoSmithKline to Acquire the Leading Dry Mouth Brand, Biotene10
. AUDIO from Medialink and GlaxoSmithKline: Give Kids A Boost For Their Health!11
. GlaxoSmithKline Acquires Sirtris Pharmaceuticals, Inc., a World Leader in Sirtuin Research and Development